A nurse is teaching a client who has a prescription for warfarin. Which of the following statements by the client indicates an understanding of the teaching?

Citalopram is a selective serotonin reuptake inhibitor(SSRI) used to manage major depressive disorder by increasing serotonin levelsin the synaptic cleft. While generally well-tolerated, SSRIs can cause serotonin syndrome, a potentially fatal condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. Early detection of neurological changes is vital.

Rationale:

A.Bruxism, or involuntary teeth grinding, is a known side effect of SSRIs that typically occurs during sleep. While it can cause dental wear and jaw pain, it is not a life-threatening emergency requiring immediate reporting. The nurse can suggest a mouth guard or a dosage adjustment during a routine follow-up with the provider to manage this specific discomfort.

B.Insomnia is a frequent side effect of citalopram due to the stimulating effects of increased serotonin in certain brain pathways. While significant for the client's quality of life, it is an expected reaction that often subsides after several weeks of therapy. It does not carry the same degree of clinical urgency as symptoms indicating acute toxicity or systemic physiological distress.

C.Weight loss can occur during the initial phase of citalopram therapy due to decreased appetite or nausea. While the nurse should monitor the client's nutritional intake and weight over time, it is a gradual process rather than an acute crisis. It is considered a manageable side effect that rarely requires immediate medical intervention unless the weight loss becomes extreme.

D.Confusion is a priority finding because it may indicate the onset of serotonin syndromeor significant hyponatremia, which are serious complications of SSRI therapy. Altered mental status is a "red flag" symptom that suggests systemic toxicity rather than a benign side effect. The nurse must report confusion immediately to ensure the client is evaluated for potentially life-threatening drug reactions.

Simvastatin is an HMG-CoA reductase inhibitorused to treat dyslipidemia by reducing hepatic cholesterol synthesis. While effective for cardiovascular prophylaxis, it carries risks of hepatotoxicityand myopathy. Clinical monitoring focuses on liver function tests and markers of muscle integrity to detect early signs of statin-inducedorgan injury.

Rationale:

A.Decreased creatine kinase (CK) is not a finding of clinical concern; however, increased CK would be highly significant. Elevated CK levels indicate muscle breakdown or rhabdomyolysis, which is a rare but severe side effect of statin therapy. A low or normal CK level suggests that the medication is not currently causing significant damage to the client's skeletal muscle tissue.

B.Increased alkaline phosphatase is a marker of potential liver injury or biliary obstruction and must be reported to the provider immediately. Since simvastatin is processed by the liver, it can cause asymptomatic elevations in liver enzymes or, in rare cases, drug-induced hepatitis. The nurse must monitor for jaundice and upper quadrant pain when these laboratory values are elevated.

C.Increased HDL is a positive therapeutic outcome of simvastatin therapy and does not need to be reported as an adverse finding. High-density lipoprotein is the "good" cholesterol that aids in the transport of cholesterol away from the arteries. An increase in this value indicates that the medication and lifestyle changes are successfully reducing the client's overall cardiovascular risk profile.

D.Decreased HbA1c is generally a favorable finding, as it indicates improved long-term glucose control. Statins have actually been associated with a slight increase in HbA1c and blood glucose levels in some patients, potentially increasing the risk of diabetes. Therefore, a decrease would not be considered a medication-related adverse effect that requires urgent notification to the healthcare provider.